Belantamab Mafodotin-Blmf

Introduction of Belantamab Mafodotin-Blmf

Belantamab Mafodotin, sold under the brand name Blenrep, is a medication for the treatment of relapsed and also refractory multiple myeloma. Belantamab Mafodotin-blmf is in fact an antibody-drug conjugate. This medication is classified as a B-cell maturation antigen (BCMA)-directed antibody and also microtubule inhibitor conjugate. However, experts indicate Belantamab Mafodotin-blmf for the treatment of multiple myeloma in patients who are not responding to standard therapy or in those whose cancer comes back after remission. 

Belantamab mafodotin is a humanized IgG1κ monoclonal antibody against the B-cell maturation antigen (BCMA) conjugated with a cytotoxic agent, maleimidocaproyl monomethyl auristatin F (mcMMAF). The antibody-drug conjugate binds to BCMA on myeloma cell surfaces causing cell cycle arrest and also inducing antibody-dependent cellular cytotoxicity.

Hwever, experts indicate Belantamab mafodotin for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. 

Experts give Belantamab Mafodotin-blmf as an intravenous infusion (IV) into the vein. This medication is, in fact, given by injection into a vein as directed by your doctor, usually every 3 weeks. However, the injection is given by a health care professional, usually over about 30 minutes.

Side Effects:

  • Eye problems including the formation of bands in the front of the eye leading to a change in eyesight (keratopathy).
  • Hyperglycemia
  • Hypoalbuminemia
  • Increased liver enzymes
  • Low blood counts
  • Gastrointestinal disorders (nausea, constipation, or diarrhoea)
  • Decreased appetite
  • Fatigue
  • Fever
  • Joint and back pain
  • Increased risk of upper respiratory infections
  • Increased serum creatinine
  • Infusion reaction
  • Blurred vision and dry eyes

Contact your health care provider immediately, if you should experience any of the following symptoms:

  • Fever of 100.4º F (38º C) or higher, chills (possible signs of infection)
  • Infusion reactions including:
    • Redness of your face
    • Itching or rash
    • Shortness of breath, coughing or wheezing
    • Swelling of your lips, tongue, throat or face
    • Dizziness
    • Feel like passing out
    • Tiredness
    • Feel like your heart is racing (palpitations)

The following symptoms require medical attention but are not an emergency. Nausea (interferes with the ability to eat and unrelieved with prescribed medication)

  • Diarrhoea (4-6 episodes in a 24-hour period)
  • Unusual bleeding or bruising
  • Black or tarry stools, or blood in your stools
  • Blood in the urine
  • Pain or burning with urination
  • Extreme fatigue (unable to carry on self-care activities)
  • Mouth sores (painful redness, swelling or ulcers)


  • Before using belantamab mafodotin, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems.
  • Eye problems are common with this medication. You should use prescriptive-free lubricant eye drops during treatment and avoid wearing contact lenses.
  • Do not receive any kind of immunization or vaccination without your doctor’s approval while taking Belantamab Mafodotin-blmf.
  • Inform your health care professional if you are pregnant or may be pregnant prior to starting this treatment.  If you become pregnant while taking Belantamab Mafodotin-blmf, stop taking the medication immediately and call your doctor for further instructions.
  • Do not breastfeed while taking Belantamab Mafodotin-blmf and for 3 months after the last dose.
  • Drink at least two to three quarts of fluid every 24 hours, unless you are instructed otherwise.
  • Use an electric razor and a soft toothbrush to minimize bleeding.
  • In general, drinking alcoholic beverages should be kept to a minimum or avoided completely.